Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:53 AM
Ignite Modification Date: 2025-12-25 @ 3:53 AM
NCT ID: NCT06641102
Eligibility Criteria: Inclusion Criteria: * Aged 21 to 70 * Chronic Back Pain- CBP will be defined according to the criteria established by a recent NIH task force * Pain duration must be at least 3 months, with back pain being an ongoing problem for at least half the days of the last 6 months. That is, patients can meet criteria by either reporting pain every day for the past 3 months, or by reporting pain on half or more of the days for the past 6+ months. * Patients must rate pain intensity at 4/10 or greater on the Brief Pain Inventory-Short Form (BPISF) (on the item measuring average pain over the last week). * Participants must also be comfortable and able to communicate via email or text message, as several study measures are collected in this manner. * Able to use a smartphone Exclusion Criteria: * Back pain associated with compensation or litigation issues as determined by self-report within the past year * Leg pain is greater than back pain, as this suggests neuropathic pain, which may be less responsive to psychotherapy * Cauda Equina syndrome, as screened for by self-reported inability to control bowel or bladder function * Self-reported diagnoses of schizophrenia, multiple personality disorder, or dissociative identity disorder * Self-reported use of intravenous drugs, due to concerns about infections and subject compliance with experimental protocols
Healthy Volunteers: False
Sex: ALL
Minimum Age: 21 Years
Maximum Age: 70 Years
Study: NCT06641102
Study Brief:
Protocol Section: NCT06641102